Saturday 17 October 2026 Export KMDA’s income statement to Excel — free account

Kamada Ltd.

KMDA Healthcare Drug Manufacturers Specialty & Generic

Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024. In the quarter to June 2026, revenue grew 22.7%, EPS grew 23.1%, free cash flow grew 165.7% and total debt fell 38.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

7.77 0.06 −0.77%

Follow KMDA

Alert me

Market cap: $451.7M
P/E: 20.4×
Fwd P/E: 0.0×
Dividend yield: 5.41%
F-score: 7/9
Altman Z: 3.33
Beneish M: −2.35
Dividend safety: 50/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.65

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	2	—

Insider Ownership 45.31%

Capital & Financial Ratios $m

Market Cap 451.71

Revenue 191.85

Net Income 22.25

Free Cash Flow 26.32

Net Debt (64.10)

Current Ratio 4.06

Debt/Equity 0.02

P/E ratio 20.45

Fwd P/E 0.00

P/S ratio 2.34

P/B ratio 1.67

Past 5Y EPS Growth (1.63%)

This Y EPS Growth 30.95%

Next Y EPS Growth 20.77%

Next Y revenue growth 9.48%

Next 5Y EPS Growth 21.04%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 55.42%

10-year low 10-year high

P/S against its own 10 years 72.06%

10-year low 10-year high

P/B against its own 10 years 50.57%

10-year low 10-year high

EV/Sales against its own 10 years 74.97%

10-year low 10-year high

EV/FCF against its own 10 years 44.20%

10-year low 10-year high

Dividends

Payout Ratio 1.11

Annual Dividend Rate 0.42

Annual Dividend Yield 5.41%

	total	individual payouts
2026	0.42	0.25 0.17
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	56	78	75	70
Receivables	26	27	33	43
Inventory	88	79	85	87
Other	—	—	—	—
	170	184	193	200

	2023	2024	2025	Q'26
Payables	33	37	35	41
ST’ Debt	15	10	10	6
Other	—	—	—	—
	50	49	47	49

Compound Annual Growth %

	10y	5y	3y
Sales	9.95%	6.25%	11.74%
Cash Flow	0.00%	5.94%	(3.75%)
Earnings	0.00%	3.34%	0.00%
Book Value	14.01%	8.54%	15.20%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	45	55	—	—	—
’25	44	45	47	45	180
’24	38	42	42	39	161
’23	31	37	38	36	143
’22	28	24	32	45	129
’21	25	24	23	31	104
’20	33	33	35	32	133

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	18	—	—	—
’25	(1)	8	10	8	25
’24	1	14	22	10	48
’23	(3)	2	1	4	4
’22	5	11	5	7	29
’21	2	(3)	(3)	(5)	(9)
’20	(2)	11	(2)	13	19

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	16	—	—	—
’25	(2)	6	7	5	16
’24	(2)	11	20	7	37
’23	(4)	1	(1)	2	(2)
’22	5	10	4	6	25
’21	2	(5)	(4)	(6)	(13)
’20	(3)	10	(4)	11	14

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.07	0.16	—	—	—
’25	0.07	0.13	0.09	0.06	0.35
’24	0.04	0.08	0.07	0.07	0.25
’23	(0.04)	0.04	0.06	0.09	0.15
’22	(0.04)	(0.09)	0.01	0.07	(0.05)
’21	0.06	0.02	(0.02)	(0.11)	(0.05)
’20	0.12	0.08	0.15	0.04	0.38

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	3.26	3.75	4.35	4.91	4.40	5.11	3.72	4.02	4.74	5.54	Analyst estimates 2026–2028 Powerpack
	High	6.29	8.61	6.45	8.00	13.33	8.16	6.88	6.35	6.53	9.15
People
People	Employees	377	413	408	429	408	357	380	378	420	462
	Revenue/emp, $m	0.21	0.25	0.28	0.30	0.33	0.29	0.34	0.38	0.38	0.39
Income, $m
Income, $m	Revenue	77	103	114	127	133	104	129	143	161	180
	Gross margin, %	27.56	31.21	36.23	39.11	35.69	29.26	36.11	38.94	43.47	42.34
	EBT	(5)	7	20	23	19	(2)	(2)	8	13	23
	EBT margin, %	(6.47)	6.97	17.77	18.07	13.93	(1.82)	(1.75)	5.91	8.28	13.00
	Net income	(7)	7	22	22	17	(2)	(2)	8	14	20
	Depreciation	4	4	4	5	5	6	12	13	14	15
Per share, $
Per share, $	Revenue	2.13	2.71	2.84	3.15	3.02	2.31	2.89	2.92	2.80	3.13
	Earnings	(0.18)	0.18	0.55	0.55	0.39	(0.05)	(0.05)	0.17	0.25	0.35
	Cash flow	0.05	0.10	0.26	0.68	0.43	(0.20)	0.64	0.09	0.83	0.44
	Capex	(0.07)	(0.11)	(0.07)	(0.06)	(0.12)	(0.08)	(0.08)	(0.12)	(0.19)	(0.17)
	Free cash flow	(0.02)	(0.01)	0.19	0.63	0.31	(0.28)	0.55	(0.03)	0.64	0.27
	Book value	1.83	2.36	2.79	3.36	4.05	3.95	3.93	5.00	4.51	4.67
	Shares, m	36	38	40	40	44	45	45	49	57	58
Valuation, ×
Valuation, ×	P/E	0.00	28.24	9.09	12.65	16.62	0.00	0.00	38.50	23.42	20.17
	P/S	2.75	1.77	1.76	2.17	2.15	2.84	1.44	2.11	2.18	2.26
	P/B	3.19	2.04	1.79	2.04	1.60	1.67	1.06	1.23	1.35	1.51
	EV/Sales	2.40	1.37	1.33	1.59	1.33	3.03	1.54	1.90	1.82	1.95
	EV/FCF	(265.24)	(283.02)	19.75	8.00	12.99	(25.02)	8.02	(177.28)	7.94	22.50
Cash, $m
Cash, $m	Operating cash flow	2	4	11	28	19	(9)	29	4	48	25
	Capex	(3)	(4)	(3)	(2)	(5)	(4)	(4)	(6)	(11)	(10)
	Free cash flow	(1)	0	8	25	14	(13)	25	(2)	37	16
Balance, $m
Balance, $m	Working capital	50	67	87	111	153	76	63	120	135	146
	Total debt	2	2	1	1	0	38	47	15	10	10
	Net debt	(27)	(41)	(49)	(73)	(109)	19	13	(41)	(68)	(66)
	Shareholders’ equity	67	89	112	135	179	177	176	244	259	269
Returns, %
Returns, %	ROA	(6.68)	6.22	17.14	14.27	8.92	(0.84)	(0.72)	2.45	3.98	5.38
	ROIC	(8.59)	9.60	19.13	22.91	17.26	(0.22)	1.50	3.09	6.55	8.06
	ROE	(9.67)	8.83	22.09	17.97	10.92	(1.25)	(1.32)	3.94	5.74	7.64

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IRWD Ironwood Pharmaceuticals, Inc.	$623.0M	4.4×	2.8×	+32.62% (above 0%: growing)	+106.67% (above 0%: growing)	+486.70% (above 0%: growing)	100.00%	70.16%	Compare
AQST Aquestive Therapeutics, Inc.	$509.6M	— (loss-making)	— (loss-making)	+38.15% (above 0%: growing)	n/m	−20.35% (below 0%: shrinking)	70.93%	(59.51%)	Compare
EVO Evotec AG	$504.4M	— (loss-making)	— (loss-making)	−12.98% (below 0%: shrinking)	n/m	−9,727.20% (below 0%: shrinking)	(1.00%)	(77.50%)	Compare
EOLS Evolus, Inc.	$500.0M	— (loss-making)	— (loss-making)	+21.18% (above 0%: growing)	n/m	+84.90% (above 0%: growing)	68.00%	(5.40%)	Compare
TLRY Tilray Brands, Inc.	$474.4M	— (loss-making)	— (loss-making)	+22.74% (above 0%: growing)	n/m	−36.60% (below 0%: shrinking)	30.14%	(9.35%)	Compare
KMDA Kamada Ltd.	$451.7M	20.4×	— (loss-making)	+22.72% (above 0%: growing)	+23.08% (above 0%: growing)	+165.71% (above 0%: growing)	40.91%	17.32%
TKNO Alpha Teknova, Inc.	$408.0M	— (loss-making)	— (loss-making)	+18.45% (above 0%: growing)	n/m	+74.18% (above 0%: growing)	40.09%	(23.72%)	Compare
EBS Emergent Biosolutions Inc.	$368.1M	— (loss-making)	— (loss-making)	+66.29% (above 0%: growing)	n/m	−47.68% (below 0%: shrinking)	58.56%	(53.39%)	Compare
CGC Canopy Growth Corporation	$311.2M	— (loss-making)	— (loss-making)	+12.41% (above 0%: growing)	n/m	−117.60% (below 0%: shrinking)	27.40%	(27.24%)	Compare
Median of peers	$487.2M	—	—	+21.96%	—	−28.47%	49.32%	(25.48%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Kamada Ltd. (KMDA) key facts

Strength: Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024.
Strength: Net income was $20.2 million, or $0.35 per share (basic), a net margin of 11.2%.
Kamada Ltd. (KMDA) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, KMDA traded at $7.77, a market capitalization of $451.7 million.
At that price the stock trades at 20.4× trailing-twelve-month earnings and 2.3× sales; its P/E is higher than 55% of its own readings over the past ten years.
Kamada Ltd. pays an annual dividend of $0.42 per share, a yield of 5.41%, with a payout ratio of 110.5%.
Return on equity was 7.64% and debt-to-equity 0.02.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 3.33 (safe zone) for fiscal 2025.